The wait is cut from weeks to hours
A new test promises to diagnose brain tumours in hours. Not weeks. It is a pilot study. The scheme is now being offered to some NHS patients, using rapid genetic testing to produce a diagnosis that previously took a very long time. For those with suspected brain tumours, this change reduces an agonising period of uncertainty, which could stretch over many weeks for both the individual and their family, into a single afternoon. The wait is cut dramatically. It allows doctors to plan treatment much sooner.
Previously, the process was slow. Very slow. A diagnosis could not be confirmed until a laboratory had analysed a tissue sample, a procedure that often involved sending the biopsy to a specialist centre located somewhere else in the country. This meant patients and their families faced a long delay. They waited for weeks. During this time, no definitive treatment plan could be made, and the exact nature of the tumour remained completely unknown, prolonging a period of intense anxiety for everyone involved. It was a system defined by the gap between the initial surgery and the final result.
The new pilot programme changes this completely. It aims to deliver a diagnosis in hours. A genetic test provides the crucial information. This is a profound shift. The pilot study uses rapid genomic sequencing, a technique that can identify the specific type of brain tumour very quickly. Instead of waiting for a sample to be posted, analysed, and reported on over several weeks, the information can now be available to surgeons and oncologists almost immediately, sometimes even while the patient is still in the operating theatre. This is what experts are calling a transformation in diagnosis and treatment. The change is significant.
Reports on 24 September 2026 confirmed the pilot's existence. The contrast is stark. A patient undergoing a biopsy under the old system would return home to wait, suspended between hope and fear for weeks on end with no clear path forward. Under the pilot scheme, that same patient could receive a detailed diagnosis on the same day as their procedure, sometimes before they have fully recovered from the anaesthetic. Treatment can begin sooner. This speed is not just about alleviating the emotional strain of waiting for a life altering result. It is also about giving clinicians the ability to act decisively, armed with precise genetic information about the specific type of aggressive tumour they need to fight. The potential is enormous.
Life in the diagnostic gap
The patient’s journey used to begin with brain surgery. This was not an operation to remove the growth. It was an invasive procedure just to get a diagnosis. A neurosurgeon would cut into the skull to perform a biopsy, taking a small sample of the tissue for analysis. This operation carries its own significant risks, from infection to brain damage, and required a hospital stay and a period of physical recovery. The sample was everything. Once it was secured, the patient was moved to a ward. Their wait had just begun. For their family, the wait had begun too.
That small piece of living tissue would then start its own journey across the country. It was not analysed in the hospital where the surgery took place. The sample was carefully preserved in formalin, placed in a specimen pot, and dispatched by courier to a specialised neuropathology laboratory. There are only a few of these centres in the United Kingdom. This meant a sample taken in Cardiff might travel to a lab in London, or tissue from a patient in Manchester could be sent to a centre in Newcastle. This logistical chain, dependent on couriers and transport networks, could add days to the process before a scientist even looked at the sample.
Then came the wait. This was the diagnostic gap. The patient would go home from hospital to recover from their operation, living in a state of suspended animation for weeks. They waited for a phone call. They waited for a letter. During this time, which could last up to six weeks, no definitive treatment plan could be made. Clinicians could not act without knowing the exact type, grade, and molecular nature of the tumour. This period of intense uncertainty was a defining feature of the old system. It was a terrible time.
This delay was not a failure of individual doctors. It was a structural problem. The expertise required to accurately identify the hundreds of different types of brain tumour was highly concentrated. Traditional laboratory methods, involving fixing the tissue in wax, slicing it thinly, and staining it for microscopic examination, are meticulous and slow. They could not be rushed. The system had a fixed speed. That speed was measured in weeks, not hours.
How the new test works
The new test works differently. It is fast. Instead of a long journey by courier to a specialised laboratory in London or Newcastle, the diagnosis can now happen within the same hospital building, sometimes just metres from the operating theatre itself. The sample avoids the formalin pot. It avoids the wax block. The tissue is analysed immediately using a process of rapid genomic sequencing, a technique which reads the tumour's fundamental genetic instructions to find out exactly what it is and how it behaves.
The science is complex. The principle is simple. A small sample of the tumour, taken during the biopsy, is placed inside a specialised sequencing machine. This machine does not rely on a pathologist's eye and a microscope. It reads the cancer’s DNA. The machine itself does not provide a name. It provides raw data. It generates millions of short strands of genetic code, which a powerful computer must then stitch together like a vast digital jigsaw puzzle to reconstruct the tumour's unique genome. This profile is compared against a library of known tumour types. A match is found. A diagnosis is made. The whole process takes hours.
This speed creates a new possibility. The intraoperative diagnosis. It means that while the patient is still asleep, the surgical team can receive a full genetic report on the tumour they are removing. This is a profound shift. For the neurosurgeon, this information is actionable intelligence, the difference between closing the patient up or deciding to pursue a more aggressive resection of the tumour margin. That decision can be made with the confidence of knowing exactly what they are fighting. The diagnosis arrives on a screen. In the theatre. Not in a letter weeks later.
This is more than a faster system. It is a more precise one. The genetic blueprint provides a far richer classification than was possible by observing cell shape alone. The result is not merely the name of a tumour, like glioblastoma. It is a detailed report on that specific tumour’s genetic weaknesses. This allows an oncologist to look beyond standard chemotherapy and choose from a growing arsenal of targeted drugs, each designed to attack a specific mutation found in the report. It moves diagnosis from a simple label to a detailed set of instructions. This is precision medicine. The NHS is piloting it.
Who gets the test now
For now, the test is not available to everyone. It is part of an NHS pilot study. Access is limited. The programme is designed to test the technology inside a working hospital before any commitment is made to a national rollout. This is a trial. Its purpose is to generate evidence, not to provide a universal service. The data gathered will inform future decisions on whether the system is effective, affordable, and practical enough for the entire health service. Only a few patients will benefit at first.
Availability is a postcode lottery. The study is confined to a small number of specialist NHS trusts, the specific hospitals chosen for their existing expertise in neurosurgery and genomic medicine. Patients treated elsewhere will not have access. They get the old diagnosis. The trial centres are those already equipped with the sequencing machines and the highly trained bioinformaticians needed to interpret the complex genetic data. This is a resource intensive process. It cannot be started everywhere at once. Concentrating the pilot in a few locations allows the NHS to test the entire diagnostic pathway, from the operating theatre to the laboratory and back to the clinician, without needing to immediately fund a vast new infrastructure across dozens of hospitals.
Selection for the trial is not automatic. Clinicians decide. A patient must meet specific criteria to be considered for inclusion in the study, though the exact requirements have not been made public. These decisions are typically made by a multi disciplinary team of surgeons, oncologists, and pathologists. They will assess each case. The focus is likely on patients with suspected high grade tumours where the speed of a diagnosis could have the most significant impact on treatment planning and outcome. Participation is voluntary. Every patient, or their family, must give informed consent to be part of the pilot, understanding that they are participating in a research study. Without that consent, the test cannot be performed.
The scale of the pilot is deliberately small. Official patient numbers and the study’s precise duration remain unconfirmed. Such trials typically begin with a few dozen individuals before expanding, gathering data methodically over a period of one to two years. The goal is not speed. The goal is rigour. Each case will be analysed to confirm the accuracy of the rapid diagnosis against the slower, established methods. They will track patient outcomes. They will measure the test's real world impact on treatment decisions. This body of evidence is what will ultimately be presented to the National Institute for Health and Care Excellence, the organisation that must approve new treatments before they can be funded and adopted as standard practice across the NHS in England. The process is long. A final decision could be years away.
The obstacles to a national rollout
A national rollout is not simple. The primary obstacle is money. Genomic sequencing machines are expensive, with advanced models costing hundreds of thousands of pounds each. To equip hospitals across the country would require a capital investment programme running into many millions, a significant financial commitment for an NHS already facing budgetary pressures. It is a huge sum. This is not just about the initial purchase. The machines need dedicated laboratory space, regular maintenance, and a constant supply of costly chemical reagents to function, creating a recurring operational cost that every trust would have to absorb. That is a difficult calculation. Without a central funding initiative from the government or NHS England, widespread adoption will depend on the wealth of individual trusts, creating an inevitable postcode lottery for patients.
Then there is the issue of staff. These machines need experts. The NHS needs more clinical scientists and bioinformaticians trained in genomics to operate the sequencers and, crucially, to interpret the vast quantities of data they produce. This is a highly specialised field. There is already a national shortage of these professionals, and competition for their skills is fierce, not least from the private sector. Training existing pathology staff is an option, but this is a slow and expensive process that takes years and pulls them away from other duties. A full rollout would demand a coordinated national recruitment and training drive. It would need to start now. The success of the technology is entirely dependent on having enough of the right people in the right places, a challenge that cannot be solved just by buying more equipment.
Finally, there is the formal approval process. The pilot study must prove its case. Before any new diagnostic tool becomes standard practice, it must be approved by the National Institute for Health and Care Excellence, or NICE. This is a rigorous, evidence based process. The institute will not only require proof that the rapid test is as accurate as the established, slower methods, but also that it is cost effective for the health service. Analysts will build economic models. They will weigh the high upfront cost of the technology against the potential long term savings from faster treatment, shorter hospital stays, and avoiding ineffective therapies. The data from the pilot study will be essential. This process can take years, and a positive recommendation is never guaranteed. NICE approval is the final hurdle.
This is a new kind of care
This is more than speed. It is a new way to see cancer. This is personalised care. For decades, oncologists classified tumours based on their location in the body and their appearance under a microscope. A brain tumour was a brain tumour. That view is now obsolete. The science has moved on. We now know that two tumours in the same part of the brain can be genetically distinct, behaving in completely different ways and responding to entirely different kinds of drugs.
Knowing a tumour’s genetic code changes everything. It is the difference between a blunt instrument and a precision key. Doctors can move past broad spectrum chemotherapy that attacks all fast growing cells, targeting instead a specific vulnerability found only inside the cancer’s own DNA. Some tumours, for instance, have a mutation in a gene called BRAF. A fast genetic test can find it. Specific drugs exist that target only cancer cells with that exact BRAF mutation, leaving healthy tissue largely untouched. This is the goal. Get the right drug first. Avoid treatments that will fail.
The implications for patients are profound. The physical toll of ineffective treatment is reduced. It gives them a clearer prognosis. It can also offer hope where previously there might have been none, matching them to a specific drug or even a clinical trial for a newly developed targeted therapy. The information is power. It gives patients options.
The pilot study creates a vast new resource. It is a library of British cancer data. Each tumour sequenced adds to a national database, a biobank of anonymised genetic information that connects a tumour’s DNA to the patient’s treatment outcome. Researchers can use it. Scientists at institutions like The Institute of Cancer Research in London can mine this data for new patterns and identify new genetic markers for future drugs. This is how science progresses. Every patient tested is therefore not just receiving a diagnosis. They are contributing to a national research effort which could help countless others, creating an infrastructure for cancer discovery that will serve the UK for decades. Every diagnosis becomes a gateway to better science.
Sources. BBC News Health: From weeks to hours - the rapid new test transforming brain tumour diagnosis. Sky News Technology: New brain tumour test could 'transform' diagnosis and treatment.
Analysis. Drafted with AI assistance from the sources listed above and reviewed by an editor before publication. Jnews links to the organisations it writes about.
